January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

ALX Oncology Holdings Inc.’s ALXO share price has surged by 11.88%, which has investors questioning if this is right time to ...

When President Donald Trump's administration abruptly paused external communications, hiring, travel and grant-review panels ...

Immunotherapy treatment was effective at reducing attack recurrence in patients with NMOSD but was less effective for MOGAD, a study found.

The following is a summary of “Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study,” ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...